Capecitabine-induced cardiotoxicity mimicking myocardial infarction

Şentürk, Tunay; Kanat, Özgür; Evrensel, Türkkan; Aydınlar, Ali

doi:10.1007/bf03086265

Cited by 18 publications

(9 citation statements)

References 14 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The risk of HF remains higher for patients who receive anthracyclines compared with those who receive other agents, even after excluding elderly patients and those with relevant comorbidities . Cancer treatment‐induced HF occurs with several other traditional chemotherapeutic agents, including cyclophosphamide (7%‐28%)and docetaxel (2.3%‐8%) (Table ) . The potential for permanent cardiac damage with exposure to anthracyclines has led to the adoption, in some clinical settings (ie, early stage breast cancer), of chemotherapy regimens with lower cumulative anthracycline exposure.…”

Section: Common CV Adverse Eventsmentioning

confidence: 99%

Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management

Curigliano

Cardinale

Dent

et al. 2016

CA A Cancer J Clinicians

565

427

View full text Add to dashboard Cite

Answer questions and earn CME/CNE Cancer and heart disease are the leading causes of morbidity and mortality in the industrialized world. Modern treatment strategies have led to an improvement in the chances of surviving a diagnosis of cancer; however, these gains can come at a cost. Patients may experience adverse cardiovascular events related to their cancer treatment or as a result of an exacerbation of underlying cardiovascular disease. With longer periods of survival, late effects of cancer treatment may become clinically evident years or decades after completion of therapy. Current cancer therapy incorporates multiple agents whose deleterious cardiac effects may be additive or synergistic. Cardiac dysfunction may result from agents that can result in myocyte destruction, such as with anthracycline use, or from agents that appear to transiently affect left ventricular contractility. In addition, cancer treatment may be associated with other cardiac events, such as severe treatment-induced hypertension and vasospastic and thromboembolic ischemia, as well as rhythm disturbances, including QTc prolongation, that may be rarely life-threatening. Early and late effects of chest radiation can lead to radiation-induced heart disease, including pericardial disease, myocardial fibrosis, cardiomyopathy, coronary artery disease, valvular disease, and arrhythmias, in the setting of myocardial fibrosis. The discipline of cardio-oncology has developed in response to the combined decision making necessary to optimize the care of cancer patients, whether they are receiving active treatment or are long-term survivors. Strategies to prevent or mitigate cardiovascular damage from cancer treatment are needed to provide the best cancer care. This review will focus on the common cardiovascular issues that may arise during or after cancer therapy, the detection and monitoring of cardiovascular injury, and the best management principles to protect against or minimize cardiotoxicity during the spectrum of cancer treatment strategies. CA Cancer J Clin 2016;66:309-325. © 2016 American Cancer Society.

show abstract

Section: Common CV Adverse Eventsmentioning

confidence: 99%

Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management

Curigliano

Cardinale

Dent

et al. 2016

CA A Cancer J Clinicians

565

427

View full text Add to dashboard Cite

show abstract

“…Prior case reports reveal disease-free coronary arteries on angiography [24]. Other studies note the efficacy of vasodilator therapy, including nitrates and calcium channel blockers, in resolving chest pain and dynamic ECG changes in the setting of 5-FU administration [24,25]. 5-FU also has been shown in vitro to induce vasoconstriction of vascular smooth muscle cells via the activation of protein kinase C, which resolves with administration of protein kinase inhibitors [4].…”

Section: Coronary Vasospasmmentioning

confidence: 99%

“…Several studies have utilized oral capecitabine, an oral pro-drug of 5-FU, as an alternative agent to mitigate the adverse effects of 5-FU. Unfortunately, several reports still demonstrate drug-induced cardiotoxicity, albeit delayed until significant metabolite accumulation occurred [1,25]. Eskilsson et al [48] attempted to prevent vasospasm-induced 5-FU cardiotoxicity via preadministration of verapamil without significant clinical effect.…”

Section: Treatment and Prophylaxismentioning

confidence: 99%

5-fluorouracil induced cardiotoxicity: Review of the literature

Sorrentino

Kim²,

Foderaro³

et al. 2012

Cardiol J

175

138

View full text Add to dashboard Cite

show abstract

“…Endothelin-1 is a potent vasoconstrictor that has a known regulatory role in vascular vasomotor tone in coronary artery disease [39,40]. The efficacy of vasodilator therapy including non-dihydropyridine calcium channel blockers such as verapamil and nitrates were noted to be effective in resolving chest pain and dynamic ECG changes in the setting of 5-FU induced cardiotoxicity [41,42]. These data support that theory of coronary vasoconstriction as part of the pathophysiology of fluoropyrimidine-induced cardiotoxicity.…”

Section: Coronary Vasospasmmentioning

confidence: 59%

5-FU induced cardiotoxicity: case series and review of the literature

et al. 2019

View full text Add to dashboard Cite

Background: 5-Fluorouracil (5-FU) is an antimetabolite chemotherapy used for a variety of solid tumors. It has the potential to cause a wide spectrum of cardiotoxicity, ranging from asymptomatic electrocardiographic changes to cardiomyopathy and subsequent cardiac failure. Main body of the abstract: We present two descriptive cases of new-onset severe cardiomyopathy induced by 5-FU followed by a review of the literature. Conclusion: Our case series emphasizes the importance of early recognition of this rare complication and prompt cessation of 5-FU, as cardiac dysfunction in this context is potentially reversible.

show abstract

Capecitabine-induced cardiotoxicity mimicking myocardial infarction

Cited by 18 publications

References 14 publications

Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management

Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management

5-fluorouracil induced cardiotoxicity: Review of the literature

5-FU induced cardiotoxicity: case series and review of the literature

Contact Info

Product

Resources

About